Global Age-Related Macular Degeneration (AMD) Disease Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
1.3 OVERVIEW OF GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET 27
1.4 LIMITATIONS 29
1.5 MARKETS COVERED 29
2 MARKET SEGMENTATION 32
2.1 MARKETS COVERED 32
2.2 GEOGRAPHICAL SCOPE 33
2.3 YEARS CONSIDERED FOR THE STUDY 34
2.4 CURRENCY AND PRICING 34
2.5 DBMR TRIPOD DATA VALIDATION MODEL 35
2.6 MULTIVARIATE MODELLING 38
2.7 TYPE LIFELINE CURVE 38
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 39
2.9 DBMR MARKET POSITION GRID 40
2.10 MARKET END USER COVERAGE GRID 41
2.11 VENDOR SHARE ANALYSIS 42
2.12 SECONDARY SOURCES 43
2.13 ASSUMPTIONS 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 47
4.1 PESTEL 49
4.2 PORTER'S FIVE FORCES MODEL 50
5 REGULATORY FRAMEWORK 51
6 MARKET OVERVIEW 54
6.1 DRIVERS 56
6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION 56
6.1.2 INCREASING GERIATRIC POPULATION 56
6.1.3 INCREASE IN PIPELINE PRODUCTS 57
6.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS 58
6.2 RESTRAINTS 58
6.2.1 HIGH COST OF TREATMENT AND PROCEDURES 58
6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS 59
6.3 OPPORTUNITIES 60
6.3.1 INCREASING RESEARCH AND DEVELOPMENT 60
6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD 60
6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT 61
6.3.4 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD) 61
6.4 CHALLENGES 62
6.4.1 LIMITED ACCESS TO TREATMENT 62
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS 62
7 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE 63
7.1 OVERVIEW 64
7.2 DRY AMD 67
7.3 WET AMD 67
7.3.1 MEDICATIONS 68
7.3.2 ANTI-VEGF THERAPY 69
7.3.3 GENE THERAPY 69
7.3.4 SURGERY 69
8 GLOBAL AGE- RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER 70
8.1 OVERVIEW 71
8.2 HOSPITALS 74
8.3 SPECIALTY CLINICS 74
8.4 AMBULATORY SURGICAL CENTERS 75
8.5 HOME HEALTHCARE 76
8.6 OTHERS 77
9 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL 78
9.1 OVERVIEW 79
9.2 RETAIL SALES 83
9.2.1 HOSPITAL PHARMACIES 84
9.2.2 RETAIL PHARMACIES 84
9.2.3 OTHERS 84
9.3 DIRECT TENDER 84

10 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION 85
10.1 OVERVIEW 86
10.2 NORTH AMERICA 91
10.2.1 U.S. 97
10.2.2 CANADA 99
10.2.3 MEXICO 101
10.3 EUROPE 103
10.3.1 GERMANY 109
10.3.2 FRANCE 111
10.3.3 U.K. 113
10.3.4 RUSSIA 115
10.3.5 ITALY 117
10.3.6 SPAIN 119
10.3.7 NETHERLANDS 121
10.3.8 SWITZERLAND 123
10.3.9 POLAND 125
10.3.10 TURKEY 127
10.3.11 AUSTRIA 129
10.3.12 HUNGARY 131
10.3.13 NORWAY 133
10.3.14 IRELAND 135
10.3.15 LITHUANIA 137
10.3.16 REST OF EUROPE 139
10.4 ASIA-PACIFIC 140
10.4.1 CHINA 147
10.4.2 JAPAN 149
10.4.3 INDIA 151
10.4.4 SOUTH KOREA 153
10.4.5 AUSTRALIA 155
10.4.6 SINGAPORE 157
10.4.7 THAILAND 159
10.4.8 INDONESIA 161
10.4.9 PHILIPPINES 163
10.4.10 MALAYSIA 165
10.4.11 VIETNAM 167
10.4.12 REST OF ASIA-PACIFIC 169

10.5 SOUTH AMERICA 170
10.5.1 BRAZIL 177
10.5.2 ARGENTINA 179
10.5.3 PERU 181
10.5.4 REST OF SOUTH AMERICA 183
10.6 MIDDLE EAST & AFRICA 184
10.6.1 SOUTH AFRICA 191
10.6.2 SAUDI ARABIA 193
10.6.3 UAE 195
10.6.4 ISRAEL 197
10.6.5 EGYPT 199
10.6.6 KUWAIT 201
10.6.7 REST OF MIDDLE EAST & AFRICA 203
11 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY LANDSCAPE 204
11.1 COMPANY SHARE ANALYSIS: GLOBAL 204
11.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 205
11.3 COMPANY SHARE ANALYSIS: EUROPE 206
11.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 207
12 SWOT ANALYSIS 208
13 COMPANY PROFILE 209
13.1 NOVARTIS AG 209
13.1.1 COMPANY SNAPSHOT 209
13.1.2 REVENUE ANALYSIS 209
13.1.3 COMPANY SHARE ANALYSIS 210
13.1.4 PRODUCT PORTFOLIO 210
13.1.5 RECENT DEVELOPMENT 210
13.1.5.1 AGREEMENT 210
13.2 GENENTECH, INC. 211
13.2.1 COMPANY SNAPSHOT 211
13.2.2 COMPANY SHARE ANALYSIS 211
13.2.3 PRODUCT PORTFOLIO 212
13.2.4 RECENT DEVELOPMENT 212
13.3 BAYER AG 213
13.3.1 COMPANY SNAPSHOT 213
13.3.2 REVENUE ANALYSIS 213
13.3.3 COMPANY SHARE ANALYSIS 214
13.3.4 PRODUCT PORTFOLIO 214
13.3.5 RECENT DEVELOPMENT 214
13.4 ADVERUM BIOTECHNOLOGIES, INC. 215
13.4.1 COMPANY SNAPSHOT 215
13.4.2 REVENUE ANALYSIS 215
13.4.3 PRODUCT PORTFOLIO 215
13.4.4 RECENT DEVELOPMENT 216
13.5 ASTELLAS PHARMA INC. 217
13.5.1 COMPANY SNAPSHOT 217
13.5.2 REVENUE ANALYSIS 217
13.5.3 PRODUCT PORTFOLIO 218
13.5.4 RECENT DEVELOPMENT 218
13.6 GRAYBUG VISION INC. 219
13.6.1 COMPANY SNAPSHOT 219
13.6.2 REVENUE ANALYSIS 219
13.6.3 PRODUCT PORTFOLIO 219
13.6.4 RECENT DEVELOPMENT 220
13.7 GENSIGHT BIOLOGICS 221
13.7.1 COMPANY SNAPSHOT 221
13.7.2 REVENUE ANALYSIS 221
13.7.3 PRODUCT PORTFOLIO 222
13.7.4 RECENT DEVELOPMENTS 222
13.7.4.1 EVENT 222
13.7.4.2 AWARD 222
13.8 IONIS PHARMACEUTICALS 223
13.8.1 COMPANY SNAPSHOT 223
13.8.2 REVENUE ANALYSIS 223
13.8.3 PRODUCT PORTFOLIO 224
13.8.4 RECENT DEVELOPMENT 224
13.8.4.1 EVENT 224
13.9 IVERIC BIO 225
13.9.1 COMPANY SNAPSHOT 225
13.9.2 PRODUCT PORTFOLIO 225
13.9.3 RECENT DEVELOPMENT 225
13.10 JOHNSON &JOHNSON SERVICES, INC. 226
13.10.1 COMPANY SNAPSHOT 226
13.10.2 REVENUE ANALYSIS 226
13.10.3 PRODUCT PORTFOLIO 227
13.10.4 RECENT DEVELOPMENT 227
13.10.4.1 COLLABORATION 227

13.11 KODIAK SCIENCES INC. 228
13.11.1 COMPANY SNAPSHOT 228
13.11.2 PRODUCT PORTFOLIO 228
13.11.3 RECENT DEVELOPMENT 228
13.12 MEIRAGTX LIMITED 229
13.12.1 COMPANY SNAPSHOT 229
13.12.2 PRODUCT PORTFOLIO 229
13.12.3 RECENT DEVELOPMENTS 229
13.12.3.1 EVENTS 229
13.12.3.2 AWARD 230
13.12.3.3 COLLABORATION 230
13.13 OCUGEN INC. 231
13.13.1 COMPANY SNAPSHOT 231
13.13.2 PRODUCT PORTFOLIO 231
13.13.3 RECENT DEVELOPMENTS 231
13.13.3.1 INVESTMENT 231
13.13.3.2 CLINICAL TRIAL 232
13.14 PIXIUM VISION 233
13.14.1 COMPANY SNAPSHOT 233
13.14.2 REVENUE ANALYSIS 233
13.14.3 PRODUCT PORTFOLIO 233
13.14.4 RECENT DEVELOPMENT 234
13.14.4.1 AWARD 234
13.15 REGENXBIO INC. 235
13.15.1 COMPANY SNAPSHOT 235
13.15.2 PRODUCT PORTFOLIO 235
13.15.3 RECENT DEVELOPMENTS 235
13.15.3.1 EVENT 235
13.15.3.2 COLLABORATION 236
13.15.3.3 CERTIFICATION 236
14 QUESTIONNAIRE 237
15 RELATED REPORTS 240